Page 9 - Dr Reddy’s Laboratories

DRL to launch innovator brand of favipiravir, is silent on pricing

Ties up with Fujifilm for exclusive rights over Avigan for Indian market, can sell overseas too

Fujifilm to partner Dr Reddy's to sell Avigan as coronavirus treatment

Japan's Fujifilm Holdings Corp said it was partnering with Dr Reddy's Labs to sell the anti-flu drug Avigan in India and elsewhere to treat Covid-19, the respiratory disease caused by the coronavirus.

Dr Reddy's Lab expects to launch 25 products in US this fiscal year

The drug major has also earmarked a capital expenditure (capex) of Rs 1,000 crore for finding various projects during the ongoing financial year

Dr Reddy's joins other Indian firms to make Remdesivir under Gilead licence

DRL to receive technology transfer from Gilead and would need to scale up manufacturing and obtain regulatory approvals from 127 countries for marketing the drug

Nifty outlook and stock pick by HDFC Sec: Buy Dr Reddy's Labs, L&T Infotech

Looking at the strong setup on the medium term charts, it would be advisable to buy Nifty around 9,900, for the upside target of 10,300.

From Nestle India to Maruti Suzuki, impact of Covid-19 on earning estimates

Given the huge hit from lockdown, it is not surprising that 44 of the 80 companies have seen sharp cuts ranging 10% to 72%

MARKET WRAP: Sensex ends 114 pts higher, ITC surges 7%; India VIX drops 8%

All that happened in the markets today

Market Ahead, May 20: All you need to know before the opening bell

Reliance Industries will be in focus today as its mega rights issue opens today and closes on June 3

Dr Reddy's gets USFDA inspection closure report fo Srikakulam unit

The plant is one of the company's three units that were served a warning letter in November 2015 for not following the prescribed operational and manufacturing quality standards

Google sees jump in cloud infra use as India stays at home during lockdown

We're pushing limits to bring tech to every user, says Google Cloud India head Karan Bajwa

Diversified model, US outlook to help Dr Reddy's stock trade better

The company has multiple growth engines given its focus on India/emerging markets and limited competition products in the US

Wockhardt tanks 5% after it sells domestic branded ops to Dr Reddy's Labs

The deal, which could fetch a consideration amount of Rs 1,850 crore, is expected to close in the first quarter of financial year 2020-21, Wockhardt added.

Wockhardt sells part of branded biz to Dr Reddy's for Rs 1850 crore

Deal would help Wockhardt focus on international operations, novel pipeline R&D

Dr Reddy's posts Rs 570-cr net loss due to heavy impairment charge

Firm takes a Rs 1,110 crore hit with generic versions of its Nuvaring drug hitting the market; financial results run completely contra to analyst expectations

Dr Reddy's Labs nears 2-year high, regains Rs 50,000 crore m-cap

In the first 11 trading days of the current calendar year, Dr Reddy's has outperformed the market by surging 6 per cent on expectations of earnings improvement.

Pharma shares in focus; Dr Reddy's, Divi's, Granules hit 52-week highs

Lupin, Sun Pharmaceutical, Cadila Healthcare, Aarti Drugs and Aurobindo Pharma were up in the range of 2 per cent to 3 per cent.

Dr Reddy's gets nod for amalgamation of Dr Reddy's Holdings into company

21,026 votes, which accounted for the rest 0.02 per cent, were posted against the resolution, it added

Dr Reddy's reaping benefits of domestic market focus, outperforms peers

Firm has outperformed domestic pharma market in 7 of last 8 quarters

Amneal Pharma beats Dr Reddy's in launching limited-competition drug

Amneal's EluRyng is the first generic version of this low competition drug, which the company plans to launch this month

Dr Reddy's launches cancer treatment drug Bortezomib in the US market

Bortezomib is an active ingredient similar to that of the once blockbuster cancer treatment Velcade of Millennium Pharmaceuticals